Recently, the human body big data-driven micro ecological high-throughput screening and application transformation platform Shenzhen Zero Life completed a B1 round of financing of 100 million yuan, jointly invested by Songhe Capital, Yunshi Capital, Green Future, Danen Capital, and others, with Haoyue Capital serving as the exclusive financial advisor for this round of financing. Founded in 2016, Zero Life is a national high-tech enterprise specializing in the field of human microecology, with its own research and development theoretical system and core technology platform. Based on the driving force of human microecology big data and the ability to discover strains through high-throughput screening, the company has created a "three libraries and three platforms" including the human microecology big database, live bacterial library, metabolic product library, high-throughput screening platform, bioinformation platform, and application development platform. The core team of Zero One Life has been deeply involved in micro ecological research and transformation research, and has formed a series of research systems from data-driven dry experiments to theoretical driven wet experiments. The company adopts a clear indication to explore and predict strains and their metabolites associated with diseases. Since 10 years ago, the team has been accumulating queue data for target diseases, and has since built a live bacterial and metabolic product library with clear functions, Formed a differentiated advantage for the company. In recent years, Zero Life has continuously initiated and participated in organizing multiple large-scale cohort studies in China, using data-driven methods to feed back the "three databases and three platforms", such as the ten thousand oral microbiota project jointly led by Shanghai Jiuyuan; As an important participant in the first phase of the National Brain Science Program, we will assist in exploring the complex mechanisms of depression and human microbiome. Based on big data accumulation and high-throughput screening analysis, OneLife has accumulated more than 20 million cases of human big data in the field of multi omics. It has a library of strains related to skin diseases, obesity, diabetes and other indications, and a library of small molecular compounds derived from human microorganisms. OneLife will continue to consolidate the underlying technology platform, which will become the cornerstone for the subsequent transformation of more product applications. It is reported that in the field of microecological pharmaceuticals, Zero Life has accumulated a large pool of skin microbiota, entering the pipeline for atopic dermatitis. Currently, the pipeline layout covers multiple technological paths such as metabolic products, small molecules, live bacteria, and engineering bacteria. The company is also actively negotiating license out cooperation with major pharmaceutical companies. The treatment pipeline for diabetes and metabolic disease, mental disease and oral cavity will also be gradually promoted. In the large consumer business sector, Zero Life has reached strategic cooperation with China Resources Jiangzhong and Mengniu Troyi, focusing on the health of Chinese users' gut microbiota, personalized data analysis and report interpretation, suggestions for probiotic product use, and joint research and development of innovative products, jointly promoting the development of the human microbiota industry. Wang Xiaokai, CEO of Zero Life, stated that this round of financing provides important support for us to continue practicing our corporate development strategy and exploring diversified business paths. In the future, we will achieve new milestones in the application of original new drug pipelines for skin diseases, as well as commercial cooperation with downstream customers such as pharmaceuticals, food and cosmetics. We also look forward to communicating and cooperating with more industry investors and customers. Yang Zhenjun, managing partner of Haoyue Capital, stated that Haoyue Capital is honored to serve as the exclusive financing agent for the current round of Zero One Life